Gavel striking a DNA strand, symbolizing biotech patent challenges.

Patent Review Standards: What Merck v. Gnosis Means for Biotech Innovation

Reese Marlowe monogram
Reese Marlowe in Law & Justice November 2026 • 4 min read.

"A closer look at how the Supreme Court's decision impacts inter partes review and the future of pharmaceutical patents."


In the ever-evolving world of pharmaceutical patents, the U.S. Supreme Court's decision in Merck & Cie v. Gnosis S.p.A. has set a new course for inter partes review (IPR) proceedings. On October 11, 2016, the Supreme Court declined to hear Merck's appeal, solidifying the application of a deferential "substantial evidence" standard for reviewing obviousness determinations made by the U.S. Patent Trial and Appeal Board (PTAB). This decision has significant implications for companies seeking to challenge or defend patents through the IPR process.

The case revolved around Merck's U.S. Patent No. 6,011,040, which covers the use of tetrahydrofolates in natural stereoisomeric form to regulate homocysteine levels—a critical factor in cardiovascular, ocular, neurological, and skeletal health. Gnosis challenged the patent, arguing that its claims were obvious based on prior art. The PTAB sided with Gnosis, a decision that Merck appealed, leading to the Supreme Court's involvement.

This article delves into the details of the Merck v. Gnosis case, tracing the arguments presented before the PTAB, the Federal Circuit, and ultimately the Supreme Court. By examining the facts, legal arguments, and implications of this decision, we aim to provide clarity on the current standard of review for IPR proceedings and what it means for future patent disputes in the biotech industry.

AI Search Multiple angles on this topic

Patent Data and Operations

The USPTO’s Open Data Portal provides public data previously held in the Patent Examination Data System (PEDS), Bulk Data Storage System (BDSS), and some Developer Hub services; it excludes legacy PTMT and TAF patent statistic reports. The USPTO Patents Dashboard presents operational indicators including examination pendency, application backlog, production, and staffing. WIPO’s country profiles cover filings, technological fields, patents in force, and use of international IP systems, while the EPO Data Desk offers patent datasets, visualizations, and technology cartographies for exploring trends and filings.

Biotech Claim Types and Standards

The Iowa Law Review source reports that the pharmaceutical industry often views methods-of-use and treatment claims as weaker, second-tier protection than claims to the chemical compound itself, which can protect downstream uses more broadly. It also notes that process claims have received differential treatment in patent law. The listed biotech patent guides identify § 101 eligibility, written description for biological sequences, and enablement for antibody genus claims as recurring considerations after Mayo, Myriad, and Amgen. WIPO explains that patent-standard conflicts can arise when implementing a standard requires technology protected by one or more patents.

The Patent System’s Historical Milestones

The USPTO describes the patent system as shaped throughout U.S. history by inventors, lawmakers, and government employees. It currently grants patents in three categories: utility, design, and plant. PatentBrief’s curated timeline spans from Venice’s 1474 patent law to USPTO AI-inventorship guidance, illustrating the long arc of legal and technological developments in patenting. A separate overview frames U.S. biotechnology law around patents, FDA regulation, bioethics, genetic privacy, and effects on medicine, food, and daily life.

The Heart of the Matter: Unpacking the Patent Dispute

Gavel striking a DNA strand, symbolizing biotech patent challenges.

At the core of the Merck v. Gnosis dispute was U.S. Patent No. 6,011,040, which focuses on using tetrahydrofolates to manage homocysteine levels in the human body. Elevated homocysteine levels are associated with various diseases, making the methods described in the patent potentially valuable for treating and preventing these conditions.

Gnosis initiated an IPR of claims 1–3, 5, 6, 8, 9, 11-15, and 19-22 of the '040 patent, asserting that these claims were obvious. The challenge hinged on the argument that the methods described in the patent were already known or suggested by existing prior art. Claim 2, from which all the challenged claims depend, is central to understanding the dispute:

  • "2. A method of preventing or treating disease associated with increased levels of homocy[s]teine levels in the human body comprising administering at least one tetrahydrofolate in natural stereoisomeric form to a human subject."
AI Search Multiple angles on this topic

Current Biotech Patent Research

Nature Biotechnology’s patents collection includes research on how the public-health impact of the Medicines Patent Pool increases with fragmentation of intellectual property rights. Biotechnology Law Report describes its coverage as analysis of biotech patents and litigation, regulatory and legislative activity, and trade-related aspects of biotechnology; the journal says it began nearly 40 years ago. Life Sciences IP Review tracks legal and regulatory challenges for IP lawyers in biotechnology, pharmaceuticals, and medtech. A 2024 overview points to CRISPR-based therapies, personalized medicine, and biotechnological patents as developments underscoring the need for an adaptable patent framework.

Limits and Controversies in Biotech Patenting

The listed biotechnology patent guide notes that the field has rules governing what can and cannot be patented. A summary of Association for Molecular Pathology v. Myriad Genetics, Inc. (2013) reports that naturally occurring DNA sequences cannot be patented, while synthetically created complementary DNA (cDNA) can be. Other listed overviews characterize biotech patent law as complex and rapidly evolving, and identify legal, ethical, and social issues as questions for the sector. These sources frame patentability and its consequences as contested issues, rather than suggesting every biotechnological innovation qualifies for protection.

U.S. and European Biotechnology Patent Approaches

The comparative-analysis source identifies the United States and Europe as two of the most influential and developed patent systems for biotechnology. It proposes comparing their approaches to biotech patents, but the available source description does not specify particular doctrinal differences or outcomes. Accordingly, the supported comparison is limited to the source’s framing of these systems as important subjects for side-by-side analysis. The snippet does not provide enough detail to state which system is more permissive or how their rules differ.

Gnosis specifically targeted claim 11, which relates to a method where increased homocysteine levels are associated with methylene tetrahydrofolate reductase deficiency, using 5-methyl-(6S)-tetrahydrofolic acid. Gnosis contended that this claim was obvious based on the combination of three key references: Serfontein, Marazza, and Ubbink. The core argument was that these references, when combined, disclosed or suggested all the elements of claim 11, making it an obvious variation.

The Broader Impact: Navigating the New Landscape of Patent Reviews

The Supreme Court’s decision to deny certiorari in Merck v. Gnosis underscores the importance of thorough preparation and robust evidence when litigating patent validity before the PTAB. With the “substantial evidence” standard firmly in place, challengers face a higher hurdle in appealing PTAB decisions. For those in the biotech and pharmaceutical sectors, understanding these nuances is now more critical than ever. As the legal landscape continues to evolve, staying informed and strategically adapting to these changes will be paramount for protecting and challenging intellectual property rights.

AI Search Multiple angles on this topic

Expert Analysis in Patent Disputes

Vident Partners reports providing vetted patent expert witnesses for disputes involving claim construction, infringement analysis, validity challenges, and damages calculations in technology, pharmaceutical, and biotech matters. Expert Opinion on Therapeutic Patents publishes reviews and patent evaluations concerning recent claims and applications for compounds with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets. Mintz describes patent opinions as useful in product-development go/no-go decisions and, in litigation, as evidence of care taken during development and efforts to avoid infringement. The sources thus describe complementary roles for technical expertise, therapeutic-patent review, and legal opinions.

Emerging Filing Pressures

A life-sciences filing-trends source projects that patent filings will remain robust, driven by continued innovation in biologics, data science, and personalized medicine. It also anticipates a more competitive landscape, with overlapping claims and increased scrutiny from regulators and patent offices. Other listed sources identify evolving legal frameworks, international agreements, genetic engineering, patent eligibility, and enforcement challenges as topics shaping future biotech patent policy. These are presented as outlooks and areas of development, not as settled outcomes.

Patents’ Context-Dependent Effects

A 2023 study on the societal impact of patents emphasizes that effects depend on context and are relative, making real-world impact difficult to grasp. Its thematic analysis identified seven concepts as common denominators across disparate effects and impact themes. A separate source broadens biotechnology patent ethics beyond gene patents to include environmental effects of bioengineered organisms and patent holders’ moral responsibility to ensure access to essential technologies. Together, these sources place patent impacts within social, environmental, and access-related systems.

Inventors’ Experiences and Biotech Disputes

WIPO’s PCT case studies draw on the IP Advantage database, which chronicles intellectual-property experiences of inventors, creators, entrepreneurs, and researchers around the world. WIPO says the cases demonstrate how the PCT has been used to promote innovation in developed and developing countries. A profile of a biotechnology-patent pioneer describes a career shaped by mentors who saw promise in biology and patents, offering a perspective on how law and science developed together during the biotechnology revolution. Other listed case-study sources characterize biotech patent disputes as informative for stakeholders navigating intellectual-property rights and strategic decisions.

Patent evidence alongside the challenged claims

  • 43%Generic-drug challenges overturned all challenged claims in 43% of targeted patents and some claims in an additional 8%. These are separate outcomes, not a complete account of every challenge.[1]
  • 12 monthsDrug-patent reviews were completed within the statutory 12-month period. This gives a time comparison for the process, not an outcome measure for Merck’s dispute.[1]

What the patent record adds-and does not establish

The record describes Merck’s licensing connection as tenuous, and the Board concluded that Merck had not shown an adequate connection between the patent’s novel features and the commercial evidence. Those findings concern how the evidence was linked to the claims; they do not by themselves establish the broader effect on validity.[2] [3]

The biotech-focused discussion contrasts this analysis with the effort and uncertainty often involved in obtaining favorable results. It suggests why predictable use of existing knowledge may be harder to characterize in this field, without establishing that any particular invention is nonobvious.[4]

How other patent reports frame challenges

A report on generic-drug challenges says they have most often targeted patents covering new formulations or methods of use, rather than patents covering active ingredients. That describes a reported pattern; it does not classify the claims in Merck’s dispute.[1]

A separate analysis reports a significant relationship between patent validity and characteristics of the patent, its owner, prosecution, examiner, and prosecution history. This places validity in a broader set of associated factors, without specifying which factor determined the Merck result.[5]

What remains unanswered about Merck's evidence

  • How much weight did the Board give the tenuous licensing nexus relative to other evidence when assessing Merck’s position? The excerpt characterizes the nexus but does not establish its effect on the ultimate validity determination.[2] [3]

Sources

  1. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. (pubmed.ncbi.nlm.nih.gov)
  2. www.finnegan.com (www.finnegan.com)
  3. www.cafc.uscourts.gov (www.cafc.uscourts.gov)
  4. KSR Int’l Co. v. Teleflex, Inc.: No Obvious Changes for the Biotechnology Market (pmc.ncbi.nlm.nih.gov)
  5. "Determinants of Patent Quality: Evidence from Inter Partes Review Proc" by Brian J. Love, Shawn P. Miller et al. (scholar.law.colorado.edu)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What was the main focus of the patent dispute in the Merck v. Gnosis case?

The case of Merck & Cie v. Gnosis S.p.A. centered on U.S. Patent No. 6,011,040. This patent covered the use of tetrahydrofolates, in their natural stereoisomeric form, to regulate homocysteine levels in the human body. High homocysteine levels are linked to various health issues, making this method of management potentially valuable. Gnosis challenged this patent through an inter partes review (IPR) process, arguing that the patent claims were obvious given existing prior art.

2

How did the Supreme Court's decision in Merck v. Gnosis impact patent review standards?

The Supreme Court's decision in Merck & Cie v. Gnosis S.p.A. established the application of a 'substantial evidence' standard for reviewing obviousness determinations made by the U.S. Patent Trial and Appeal Board (PTAB) during Inter Partes Review (IPR) proceedings. This means that when the PTAB makes a decision on patent validity, the courts will defer to that decision if it is supported by substantial evidence. This standard makes it more challenging for parties to successfully appeal PTAB rulings, increasing the burden on those challenging a patent's validity.

3

What specific claims of the patent were challenged in the Merck v. Gnosis case and why?

The patent at the heart of the dispute, U.S. Patent No. 6,011,040, focused on the use of tetrahydrofolates to manage homocysteine levels. Claim 11 of the patent, related to a method for treating conditions associated with increased homocysteine levels, was specifically challenged by Gnosis. Gnosis argued this claim was obvious based on a combination of prior art references. This reveals how critical the precise wording of patent claims is and how prior art can be used to challenge these claims.

4

What is the role of Inter Partes Review (IPR) in the context of this case?

The Inter Partes Review (IPR) process, used by Gnosis to challenge Merck's patent, is a legal procedure before the U.S. Patent Trial and Appeal Board (PTAB). It allows third parties to challenge the validity of an issued patent based on prior art. The Merck v. Gnosis case highlights the importance of IPRs in the biotech industry, influencing how patent validity is assessed and litigated. The Supreme Court's decision directly impacts how these reviews are conducted and how easily decisions can be overturned.

5

What does the Merck v. Gnosis decision mean for the future of biotech innovation and patent disputes?

The implications of the Merck v. Gnosis case are significant for the biotech industry. With the Supreme Court upholding the 'substantial evidence' standard, challengers of patents face a higher bar in the IPR process. Companies must now prepare more thoroughly, gathering robust evidence to support their positions before the PTAB. This also means that those defending patents will find their patents more secure, as it is more difficult to overturn decisions. The legal landscape for biotech patents is changing, requiring strategic adaptability to protect and challenge intellectual property rights effectively.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.